GSK Sues Pfizer Over Alleged RSV Vaccine Patent Infringement

Pharmaceutical companies GSK and Pfizer are engaged in a legal dispute over supposed patent infringement. GSK alleges that Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, infringes on four patents related to its own RSV vaccine, Arexvy. Both vaccines received approval in the U.S. in May, with Abrysvo claiming that its development began in 2013, several years after GSK’s own RSV program. With potential RSV vaccine market opportunities estimated at over $10 billion, GSK is seeking damages, royalties, and possibly a permanent ban on Pfizer’s future U.S. vaccine sales should it win the lawsuit.

Nevertheless, despite the lawsuit, both GSK and Pfizer continue to focus on the distribution of their vaccines. In other news, companies such as Moderna, Sanofi, and AstraZeneca are also shaping the RSV vaccine market.

To read more, click here.

What We’re Reading to Learn More: 

• GSK sues Pfizer in US for patent infringement over RSV vaccine, Reuters
• GSK sues Pfizer claiming RSV vaccine patent infringement, CNBC